Finance

Lists
Why is PLRX down 4.76%?
Dive Deeper
PLRX:NASDAQ
Pliant Therapeutics Inc
$0.66
-4.76%
(-0.033) 1D
Nov 17, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PLRX...
Open
$0.70
High
$0.71
Low
$0.65
Mkt. cap
41.12M
Avg. vol.
396.00K
Volume
62.00
52-wk high
$1.67
52-wk low
$0.65
EPS
-$1.46
Beta
1.36
Shares outstanding
61.99M
No. of employees
49
Open
$0.70
High
$0.71
Low
$0.65
Mkt. cap
41.12M
Avg. vol.
396.00K
Volume
62.00
52-wk high
$1.67
52-wk low
$0.65
EPS
-$1.46
Beta
1.36
Shares outstanding
61.99M
No. of employees
49
News stories
From web sources and news partners
About Pliant Therapeutics Inc
CEO-
Employees49
Founded2015
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 1 analyst giving stock ratings to PLRX in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for PLRX in the last 3 months
Highest
Current $0.66
$2.00 (+202.94%)
Average
$2.00 (+202.94%)
Lowest
$2.00 (+202.94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Hold
Maintained
$2.00
+202.9%
11/12/2026
Brian Cheng
J.P. Morgan
Sell
Maintained
-
-
08/17/2026
Edward Nash
Canaccord Genuity
Hold
Reiterated
$3.00
+354.4%
08/13/2026
Unknown Analyst
Oppenheimer
Hold
Maintained
-
-
08/12/2026
Joseph Stringer
Needham
Hold
Maintained
-
-
08/12/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$3.00
+354.4%
05/12/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.39 / -$0.37
-5.29%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13.38M
13.58M
16.73M
17.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.69M
8.19M
7.14M
7.81M
Operating expense
21.08M
21.77M
23.86M
25.74M
Total operating expenses
21.08M
21.77M
23.86M
25.74M
Operating income
-21.08M
-21.77M
-23.86M
-25.74M
Other non operating income
-
-
-
-
EBT including unusual items
-23.58M
-20.04M
-22.37M
-24.38M
EBT excluding unusual items
-19.25M
-20.04M
-22.37M
-24.38M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23.58M
-20.04M
-22.37M
-24.38M
Net profit margin
-
-
-
-
Earnings per share
-0.35
-0.32
-0.36
-0.39
Interest and investment income
1.96M
1.73M
1.49M
1.36M
Interest expense
-136.00K
-
-
-
Net interest expenses
1.83M
1.73M
1.49M
1.36M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.71M
-21.51M
-23.61M
-25.51M
Gain or loss from assets sale
-
-94.00K
-
506.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps